-
Ribotoxic Stress, Not DNA Damage, Drives UV-Induced Cell Dea
2026-05-31
Sinha et al. (2024) reveal that ultraviolet (UV) radiation triggers cell death primarily through a ribotoxic stress response mediated by the kinase ZAK, rather than the canonical DNA damage pathway. Their time-resolved phosphoproteomic and genetic analysis uncovers critical feedback mechanisms governing apoptosis, offering new insights into cell fate decisions after UV exposure.
-
Tunicamycin: The N-Glycosylation Inhibitor for ER Stress Res
2026-05-30
Tunicamycin is the gold-standard N-glycosylation inhibitor, enabling precise induction of ER stress and modulation of inflammatory responses in both cell-based and animal models. This guide covers proven workflows, troubleshooting, and new experimental leverage based on recent literature.
-
Quizartinib (AC220): Optimizing FLT3 Inhibition Workflows in
2026-05-29
Quizartinib (AC220) revolutionizes acute myeloid leukemia research with high selectivity and potency for FLT3 inhibition, enabling robust cellular and in vivo models. This guide delivers actionable protocols, troubleshooting strategies, and cross-domain insights to maximize experimental reliability and translational value.
-
Coumestrol Drives Ferroptosis in RA Synoviocytes via TRIM3/P
2026-05-29
This study uncovers that Coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in fibroblast-like synoviocytes (FLS) from rheumatoid arthritis (RA) by stabilizing mitochondrial PMAIP1 through TRIM3 inhibition. These findings highlight Coumestrol as a research tool for dissecting cell death and inflammation pathways in RA and suggest its potential for advancing selective estrogen receptor modulator studies in autoimmune contexts.
-
Heptamethine Cyanine Dye Targets PR in HR+ Breast Cancer The
2026-05-28
This study introduces a tumor-targeted heptamethine cyanine dye (CA800-PR) that selectively suppresses progesterone receptor activity in hormone receptor-positive breast cancer. The findings demonstrate a novel approach to induce Golgi fragmentation and immunogenic cell death, offering alternatives to traditional hormone therapies.
-
SGI-1027 Enhances Everolimus-Induced Cell Death in Renal Can
2026-05-28
This study reveals that SGI-1027, a DNA methyltransferase inhibitor, induces methuosis and synergizes with everolimus to trigger apoptosis and GSDME-dependent pyroptosis in renal cancer cells by increasing lysosomal membrane permeability. These findings provide a mechanistic basis for overcoming everolimus resistance and introduce new opportunities for advanced renal cell carcinoma therapy.
-
Coumestrol Induces Ferroptosis in RA-FLS via PMAIP1 Stabiliz
2026-05-27
This study identifies Coumestrol as a potent inducer of ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) by stabilizing mitochondrial PMAIP1 via TRIM3 inhibition. The findings suggest a novel therapeutic approach for RA, emphasizing the relevance of mitochondrial stress pathways in disease modulation.
-
SERCA Inhibition and ER Stress Enhance HSC Mobilization In V
2026-05-27
Li et al. demonstrate that selective SERCA inhibition triggers mild endoplasmic reticulum (ER) stress, promoting efficient hematopoietic stem cell (HSC) mobilization via modulation of the CaMKII-STAT3-CXCR4 pathway. Their findings provide mechanistic insight into how ER stress inducers could improve clinical stem cell collection for transplantation.
-
2′3′-cGAMP/Rab18/FosB Axis Controls Cell Migration Beyond Im
2026-05-26
The reference study uncovers a novel function of 2′3′-cGAMP in regulating cell migration through a Rab18/FosB pathway, independent of its established role in innate immunity. These findings open new avenues for research into the broader physiological actions of 2′3′-cGAMP and highlight implications for both immunology and cancer cell biology.
-
Strategic Integration of EZ Cap EGFP mRNA 5-moUTP in Transla
2026-05-26
This article offers mechanistic insights and strategic guidance for leveraging EZ Cap™ EGFP mRNA (5-moUTP) in mRNA delivery, gene expression, and in vivo imaging applications. We contextualize the reagent’s engineering in light of recent advances in delivery vector design, highlight its unique attributes for translational researchers, and provide actionable protocol parameters. The discussion advances beyond typical product overviews, making the case for next-generation reporter mRNA as a cornerstone for immune-silent, high-fidelity experimental systems.
-
Fluorescein Tyramide: Amplifying Sensitivity in IHC & ISH Wo
2026-05-25
Fluorescein Tyramide delivers unparalleled signal amplification for detecting low-abundance targets in immunohistochemistry and in situ hybridization. By leveraging advanced TSA technology, it empowers researchers to accurately visualize subtle molecular changes, even in challenging neurobiological contexts.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual-Fluorescence mRNA Benc
2026-05-25
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables simultaneous mRNA uptake and protein translation tracking, supporting advanced mRNA delivery and translation efficiency assays. Its Cap 1 structure and 5-methoxyuridine modifications suppress innate immunity and enhance stability, offering robust, reproducible results for gene regulation studies.
-
Tobramycin: Optimized Workflows for Gram-Negative Bacterial
2026-05-24
Tobramycin, a highly water-soluble aminoglycoside antibiotic, enables reproducible, high-throughput studies of Gram-negative pathogens and resistance mechanisms. This article delivers advanced workflow strategies, troubleshooting expertise, and practical protocol enhancements to empower antibiotic resistance research with confidence.
-
Calnexin Dependence in CFTR Variant Rescue: Deep Profiling I
2026-05-23
Tedman et al. advance cystic fibrosis research by mapping how calnexin, a key ER chaperone, governs the expression and corrector responsiveness of over 200 clinically relevant CFTR variants. Their systematic approach uncovers domain- and mutation-specific patterns that inform more precise strategies for CFTR modulation and therapeutic development.
-
AT-406 (SM-406): Orally Bioavailable IAP Antagonist in Cance
2026-05-22
AT-406 (SM-406) is a potent, orally bioavailable antagonist of inhibitor of apoptosis proteins (IAPs) used to induce apoptosis pathway activation in cancer cells. It demonstrates low nanomolar affinity for XIAP, cIAP1, and cIAP2 and sensitizes ovarian cancer cells to carboplatin, with efficacy validated in breast cancer xenograft models. The compound is instrumental for mechanistic and translational cancer research.